| Schedule of Anti-dilutive Securities |
The
following Common Stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:
Schedule of Anti-dilutive Securities
| |
|
September 30, 2026 (Unaudited)
|
|
|
September 30, 2025 (Unaudited)
|
|
| Series L Preferred Stock 1 |
|
|
36,347 |
1
|
|
|
305,992 |
2 |
| Series M Preferred Stock 3 |
|
|
1,175,657 |
|
|
|
— |
|
| Greenshoe Rights - Series L Preferred Stock |
|
|
1,165,934 |
1
|
|
|
1,420,098 |
2
|
| Greenshoe Rights - Series M Preferred Stock 3
|
|
|
5,684,527 |
|
|
|
— |
|
| Options to purchase Common Stock |
|
|
23,902 |
|
|
|
23,902 |
|
| Warrants to purchase Common Stock |
|
|
9,393,734 |
|
|
|
1,978,375 |
|
| Total anti-dilutive securities |
|
|
17,480,101 |
|
|
|
3,728,367 |
|
| 1 |
As
of September 30, 2026, the shares of Series L Preferred Stock are convertible into shares of Common Stock at the holder’s
option using a conversion price of $11.35
per share. |
| |
|
| 2 |
As
of September 30, 2025, the shares of Series L Preferred Stock are convertible into shares of Common
Stock at the holder’s option using a conversion price of $16.05 per share.
|
| |
|
| 3 |
As
of September 30, 2026, the shares of Series M Preferred Stock are convertible into shares of Common Stock at the holder’s
option using a conversion price of $6.10
per share. |
|